Related Experiment Video
Updated: May 3, 2026
05:25
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
19.7K
Prostatic fluid free insulin-like growth factor-1 in relation to benign prostatic hyperplasia: a controlled study
Cavit Ceylan1, Ahmet Serel1, Omer Gokhan Doluoglu2
113rd Clinic of Urology, Türkiye YüksekIhtisas Training and Research Hospital, Ankara, Turkey.
Urology Journal
|January 29, 2014
Summary
Free Insulin-like Growth Factor-1 (IGF-1) is not linked to benign prostatic hyperplasia (BPH) risk. Further studies are required to understand the precise role of free IGF-1 in BPH development.
Area of Science:
- Endocrinology
- Urology
- Molecular Biology
Background:
- Insulin-like growth factors (IGFs) exhibit mitogenic and antiapoptotic properties in prostate tissue.
- Free IGF-1 mediates metabolic effects, but its involvement in benign prostatic hyperplasia (BPH) remains undetermined.
Purpose of the Study:
- To investigate the association between free Insulin-like Growth Factor-1 (IGF-1) levels and benign prostatic hyperplasia (BPH).
Main Methods:
- Quantified plasma and prostatic fluid levels of free IGF-I in 35 BPH patients and 35 controls.
- Assessed correlations between free IGF-1, prostate-specific antigen (PSA), and prostate volume.
Main Results:
- No significant differences in prostatic fluid or serum free IGF-1 concentrations were observed between BPH patients and controls.
- No correlation found between prostatic fluid free IGF-1 and PSA levels or prostate volume.
- BPH patients exhibited significantly higher prostate volumes and International Prostate Symptom Scores (IPSS) compared to controls.
Conclusions:
- Free IGF-1 is not associated with an increased risk of developing benign prostatic hyperplasia (BPH).
- Further research is necessary to fully elucidate the role of free IGF-1 in the pathophysiology of BPH.
